Valaciclovir-Hydrochloride shortage — AU supply status & alternatives

Valaciclovir-Hydrochloride

—

In shortage · Australia

VALTREX valaciclovir

In declared shortage · 🇦🇺 Australia

Critical shortage

Reading today’s signals…

• Can I substitute?

No pathway on record

prescriber decision required

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

Sept 2026

Sponsor est. via TGA — may differ by brand

Product attributes reference data we hold

Active ingredient (INN)	Valaciclovir-Hydrochloride
Brand names	VALTREX valaciclovir
Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 1 resolved event

◷

~2 months

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🇦🇺

Australia

TGA · just now

High

Verified timeline regulator events

🇦🇺 5 June 2026

high reported

🇦🇺 23 Feb 2026

high reported

🇦🇺 10 Oct 2025

Shortage resolved

Sources official regulators

🇦🇺

TGA

verified just now

verify ↗

Mederti Drug Report

Generated 3 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.